Larhrib H, Zeng X M, Martin G P, Marriott C, Pritchard J
Department of Pharmacy, King's College London, Stamford Street, London, UK.
Int J Pharm. 1999 Nov 25;191(1):1-14. doi: 10.1016/s0378-5173(99)00164-7.
Five different grades of lactose namely, anhydrous lactose, medium lactose, regular lactose, lactose crystals and foremost lactose were fractionated under similar conditions to obtain a size range of 63-90 microm and were characterised using laser diffraction and time-of-flight particle sizing techniques, scanning electron microscopy, optical microscopy image analysis, thermal gravimetric analysis and differential scanning calorimetry. Each of these lactose fractions were then blended separately with micronised salbutamol sulphate in a ratio of 67.5:1 (w/w). The mixing uniformity and percentage recovery of salbutamol sulphate in the powder blends were analysed using a validated HPLC method. The deposition profiles of the drug were determined using a 5-stage liquid impinger after aerosolisation at 60 l min(-1) via a Rotahaler. Despite the identical processing conditions, the lactose fractions were shown to differ in particle size, size distribution and concentrations of fine particles. The particles from each fraction also exhibited different surface textures and dissimilar DSC thermograms. However, all the blends of the lactose with salbutamol sulphate were found to have a relatively high uniformity of salbutamol sulphate content, as suggested by a coefficient of variation of less than 3.2%. Anhydrous and medium lactose produced a more efficient delivery of salbutamol sulphate when aerosolised from the Rotahaler in comparison to other grades of lactose. For example, the fine particle fraction (FPF) and fine particle dose (FPD) of drug from formulations containing anhydrous lactose were 13.4+/-4.2% and 57.3+/-17.6 microg, respectively, which were approximately two times higher than the respective values of the formulation containing regular lactose. Medium lactose resulted in drug FPF (7. 9+/-2.7%) and FPD (32.4+/-11.8 microg), which were significantly (ANOVA P<0.05) higher than the same parameters obtained using lactose crystals, foremost lactose and regular lactose. More efficient drug delivery from anhydrous lactose may be partly attributed to the relatively higher concentration of fine lactose in this grade of carrier, although it showed a rougher surface than the other grades of lactose. However, the relatively high FPF of the drug from medium lactose may have been due to the relatively small mean particle size and smooth surface of the particles. Therefore, the source and grade of lactose may have a substantial effect on drug delivery from dry powder inhaler formulations and care should be taken in establishing appropriate quality control parameters when selecting an appropriate grade of carrier.
对五种不同等级的乳糖,即无水乳糖、中等乳糖、普通乳糖、乳糖晶体和优质乳糖,在相似条件下进行分级,以获得63 - 90微米的粒径范围,并使用激光衍射和飞行时间颗粒粒度分析技术、扫描电子显微镜、光学显微镜图像分析、热重分析和差示扫描量热法进行表征。然后将这些乳糖级分分别与微粉化的硫酸沙丁胺醇按67.5:1(w/w)的比例混合。使用经过验证的高效液相色谱法分析粉末混合物中硫酸沙丁胺醇的混合均匀性和回收率。通过旋转吸入器以60升/分钟的流速雾化后,使用五级液体冲击器测定药物的沉积曲线。尽管加工条件相同,但乳糖级分在粒径、粒径分布和细颗粒浓度方面存在差异。每个级分的颗粒还表现出不同的表面纹理和不同的差示扫描量热图。然而,所有乳糖与硫酸沙丁胺醇的混合物中硫酸沙丁胺醇含量的均匀性相对较高,变异系数小于3.2%表明了这一点。与其他等级的乳糖相比,无水乳糖和中等乳糖从旋转吸入器雾化时能更有效地递送硫酸沙丁胺醇。例如,含无水乳糖制剂的药物细颗粒分数(FPF)和细颗粒剂量(FPD)分别为13.4±4.2%和57.3±17.6微克,分别比含普通乳糖制剂的相应值高约两倍。中等乳糖产生的药物FPF(7.9±2.7%)和FPD(32.4±11.8微克),显著高于(方差分析P<0.05)使用乳糖晶体、优质乳糖和普通乳糖获得的相同参数。无水乳糖更有效的药物递送可能部分归因于该等级载体中细乳糖的相对较高浓度,尽管它的表面比其他等级的乳糖更粗糙。然而,中等乳糖药物相对较高的FPF可能是由于颗粒的平均粒径相对较小且表面光滑。因此,乳糖的来源和等级可能对干粉吸入剂制剂的药物递送有重大影响,在选择合适等级的载体时应注意建立适当的质量控制参数。